Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxter receives final FDA order for Colleague recall

This article was originally published in Clinica

Executive Summary

The recall of Baxter International's Colleague infusion pumps in the US is to take place over the next two years. Baxter was prompted to reveal the full details of its recall plan for the products after the US FDA issued its final order concerning the action. Owners of the faulty pump may exchange the product for Baxter’s Sigma Spectrum pump, or they could receive either the pump’s depreciated value, which is no less than $1,500 for a single-channel pump or $3,000 for a triple-channel pump, or the purchase price, whichever is smaller. In May, the FDA ordered Deerfield, Illinois-based Baxter to recall and destroy all 200,000 of its Colleague infusion pumps in the US due to “a longstanding failure to correct many serious problems with the pumps”. Baxter was ordered to refund customers or replace the pumps at no cost (www.clinica.co.uk, 4 May 2010).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel